Clinical trials: Post-polycythemia Vera Myelofibrosis (PPV-MF)

Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)

Managed Access Programs for INC424, Ruxolitinib

• Available
• Age: 2 years and older
• Expanded access

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

Conditions

Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness

Trial name

NCT04745637

Testing

Ruxolitinib

Sponsor

Novartis Pharmaceuticals